Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etanercept once-weekly versus twice-weekly dosing for moderate to severe plaque psoriasis
2007-001724-12Phase 4Completed
- Sponsor
- Wyeth
- Start
- Apr 2008
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of etanercept in plaque psoriasis (2 arms), sponsored by Wyeth. Primary endpoint: Primary efficacy endpoint. Started Apr 2008; status: completed.
02
Drugs
etanercept
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on 2007-001724-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-001724-12.